Vasamed (OTCMKTS:VSMD) and Co-Diagnostics (NASDAQ:CODX) Critical Survey

Co-Diagnostics (NASDAQ:CODX) and Vasamed (OTCMKTS:VSMD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Co-Diagnostics and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-563.93%	-54.94%	-49.28%
Vasamed	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Co-Diagnostics and Vasamed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	0	1	0	0	2.00
Vasamed	0	0	0	0	0.00

Co-Diagnostics presently has a consensus target price of $1.50, suggesting a potential upside of 80.70%. Given Co-Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Vasamed.

Insider & Institutional Ownership

15.0% of Co-Diagnostics shares are held by institutional investors. 6.1% of Co-Diagnostics shares are held by insiders. Comparatively, 8.0% of Vasamed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Co-Diagnostics and Vasamed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$7.32 million	3.62	-$35.33 million	($1.38)	-0.60
Vasamed	N/A	N/A	N/A	N/A	N/A

Vasamed has lower revenue, but higher earnings than Co-Diagnostics.

Volatility and Risk

Co-Diagnostics has a beta of -0.84, indicating that its share price is 184% less volatile than the S&P 500. Comparatively, Vasamed has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Summary

Vasamed beats Co-Diagnostics on 5 of the 9 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.